Immunodiagnostic Systems
Immunodiagnostic Systems is an in-vitro diagnostic subsidiary of Revvity, Inc. that develops FDA-cleared automated chemiluminescence immunoassays for clinical laboratories, with a flagship Total Testosterone assay targeting endocrine diagnostics.
- Company typePrivate
- Founded1977
- HeadquartersBoldon, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immunodiagnostic Systems does
Immunodiagnostic Systems is an in-vitro diagnostic solution provider serving the clinical laboratory market. Founded in 1977 and headquartered in Boldon, United Kingdom, the company specializes in immunochemistry diagnostic solutions built around automated chemiluminescence immunoassay (CLIA) technology for endocrine testing. Its flagship product, the FDA-cleared Total Testosterone automated chemiluminescence immunoassay (cleared in May 2026), enables clinical laboratories to run a comprehensive testosterone testing workflow on a single platform, replacing complex traditional testing methods used in diagnosing testosterone-related disorders including hypogonadism.
The company's core technology is automated chemiluminescence immunoassay, a mature diagnostic modality in which chemiluminescent signals are measured to quantify analytes in patient samples. The platform architecture emphasizes simplified clinical workflows and reduced manual processing relative to traditional testosterone testing methods. The product portfolio is narrowly focused on endocrine diagnostics, with testosterone testing as the primary commercial driver. The company previously traded publicly on the London Stock Exchange under ticker IDH and has historically grown through acquisitions, including Suomen Bioanalytiikka Oy (2005), Biocode Hycel SA (2007), MGP Diagnostics (2010), and DiaMetra S.r.l. (2014).
Immunodiagnostic Systems operates as a subsidiary of Revvity, Inc. (NYSE: RVTY), a publicly traded diagnostics and life sciences company. The business model is hardware-and-reagent-based: revenue is generated through sale of FDA-cleared diagnostic assays and automated testing platforms to clinical laboratories and healthcare facilities, typically via quote-based enterprise contracts rather than transparent public pricing. The go-to-market leverages Revvity's established medical diagnostics distribution network, reaching US hospital and reference laboratories through direct enterprise sales and industry conferences. The company employs 251-500 people and is led by CEO Jaap Stuut. Customer concentration risk is structurally low given the horizontal clinical laboratory segment, though specific revenue figures are not publicly disclosed.
Immunodiagnostic Systems firmographics
Firmographics- Name
- Immunodiagnostic Systems
- Website
- https://idsplc.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Immunodiagnostic Systems is an in-vitro diagnostic subsidiary of Revvity, Inc. that develops FDA-cleared automated chemiluminescence immunoassays for clinical laboratories, with a flagship Total Testosterone assay targeting endocrine diagnostics.
- Ownership category
- akta.pro rank
Immunodiagnostic Systems industry classification
Industry- Product category
- In-Vitro Clinical Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)
- akta.pro secondary industry
- Clinical Chemistry & Immunoassay Systems (HLAHAAAA)
Keywords
Where Immunodiagnostic Systems is headquartered
LocationHeadquarters
- HQ city
- Boldon
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Immunodiagnostic Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Diagnostic Assays and Instruments: Revenue generated from sale of FDA-cleared diagnostic assays and automated testing platforms to clinical laboratories and healthcare facilities for endocrine disease diagnostics.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Immunodiagnostic Systems product offering
Product offeringCore offering
Immunodiagnostic Systems develops and sells FDA-cleared automated chemiluminescence immunoassay diagnostic assays and instruments for clinical laboratories. The company's core offering is the Total Testosterone automated chemiluminescence immunoassay, which runs on a single platform to deliver comprehensive testosterone testing and simplify clinical workflows for diagnosing testosterone-related disorders such as hypogonadism and other endocrine conditions.
Product overview
Immunodiagnostic Systems operates as a subsidiary of Revvity, Inc., specializing in immunochemistry diagnostic solutions. The company's product portfolio centers on automated chemiluminescence immunoassay technology for endocrine diagnostics testing. The primary offering is the Total Testosterone automated chemiluminescence immunoassay, which received FDA clearance and runs on a unified testing platform, enabling simplified clinical workflows for testosterone-related disorder diagnostics.
Differentiator
Problem solved
Functional benefit
Products and services
- Total Testosterone Automated Chemiluminescence Immunoassay FDA-cleared automated chemiluminescence immunoassay for total testosterone testing that operates on a single platform, providing a comprehensive testosterone testing solution for hospital and reference laboratories and simplifying clinical workflows for diagnosing testosterone-related disorders such as hypogonadism and other endocrine conditions.
Companies that use Immunodiagnostic Systems
Customer profileSegments1 record
Ideal customer profiles1 record
Immunodiagnostic Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Immunodiagnostic Systems partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Immunodiagnostic Systems competitors and assessment
Company assessmentDirect peers
- DiaSorin: DiaSorin is a specialty in-vitro diagnostics company whose LIAISON platform offers a broad menu of chemiluminescence immunoassays with particularly strong endocrinology and hormone test coverage, including testosterone. It is the closest direct comparable to IDS in target customer (clinical labs), technology (chemiluminescence immunoassay), and endocrinology focus.
- Beckman Coulter (Danaher): Beckman Coulter's DxI and Access immunoassay analyzers offer FDA-cleared endocrine assays including testosterone, targeting the same clinical laboratory customers as IDS with comparable automated chemiluminescence technology.
- Ortho Clinical Diagnostics: Ortho Clinical Diagnostics provides the VITROS immunoassay platform serving hospital and clinical laboratories with endocrine test menus. It is a direct peer in technology and customer base, competing for automated immunoassay placements.
- Tosoh Bioscience: Tosoh offers the AIA-PACK/ST AIA chemiluminescence immunoassay systems for clinical laboratories, including hormone and endocrine assays. It is comparable to IDS as a specialty immunoassay vendor targeting similar lab customers.
Broad incumbents
- QuidelOrtho: QuidelOrtho provides the VITROS and other immunoassay platforms across hospital and reference labs with a broad menu including endocrinology tests. It competes with IDS for clinical laboratory immunoassay placements in a similar technology category.
- Abbott Diagnostics: Abbott's Architect immunoassay platform provides a comprehensive endocrine test menu used by hospital and reference laboratories globally, including FDA-cleared testosterone assays. It is a key broad incumbent competitor for IDS's target customers and platform category.
- Siemens Healthineers: Siemens Healthineers markets the Atellica and ADVIA Centaur chemiluminescence immunoassay systems serving clinical laboratories with broad endocrine menus. It competes directly with IDS for automated immunoassay placements in hospital and reference labs.
- Roche Diagnostics: Roche operates the cobas/e601/8000 immunoassay platforms, a broad incumbent offering FDA-cleared endocrine tests including testosterone to hospital and reference laboratories worldwide. It competes with IDS for clinical lab immunoassay menu placements and instrument footprint.
- Revvity: Revvity is the parent company of Immunodiagnostic Systems and a broader life sciences and diagnostics platform. As parent, Revvity's overall diagnostics business sets the strategic and commercial context for IDS and competes in adjacent immunoassay and clinical lab testing categories.
Emerging players
- bioMérieux: bioMérieux is expanding its clinical diagnostics portfolio into immunoassay and specialty testing adjacent to IDS's space. While its core strength is microbiology, its growth into hormone and endocrine assay categories makes it a partial overlap peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Immunodiagnostic Systems social profiles
Digital presenceImmunodiagnostic Systems compliance and trust
Trust signalCompliance1 record
Immunodiagnostic Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunodiagnostic Systems leadership team
Management profileNumber of profiles
Profiles1 record
Immunodiagnostic Systems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunodiagnostic Systems M&A and investment
M&A and investmentM&A5 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunodiagnostic Systems
What does Immunodiagnostic Systems do?
Immunodiagnostic Systems develops and sells FDA-cleared automated chemiluminescence immunoassay diagnostic assays and instruments for clinical laboratories. The company's core offering is the Total Testosterone automated chemiluminescence immunoassay, which runs on a single platform to deliver comprehensive testosterone testing and simplify clinical workflows for diagnosing testosterone-related disorders such as hypogonadism and other endocrine conditions.
Is Immunodiagnostic Systems a public or private company?
Immunodiagnostic Systems is a private company. It is classified as public and is currently operating.
When was Immunodiagnostic Systems founded?
Immunodiagnostic Systems was founded in 1977. It employs 251 to 500 people.
Where is Immunodiagnostic Systems based?
Immunodiagnostic Systems is headquartered in Boldon, United Kingdom, in the Europe region.
How does Immunodiagnostic Systems make money?
One revenue line is on record: diagnostic Assays and Instruments.
Who are Immunodiagnostic Systems's main competitors?
Direct peers on record are DiaSorin, Beckman Coulter (Danaher), Ortho Clinical Diagnostics and Tosoh Bioscience. Broad incumbents are QuidelOrtho, Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics and Revvity. bioMérieux is listed as an emerging player.
Does Immunodiagnostic Systems have an API?
No public API is recorded for Immunodiagnostic Systems.
What industry is Immunodiagnostic Systems in?
Immunodiagnostic Systems's product category is In-Vitro Clinical Diagnostics. Its primary akta.pro industry code is HLAAALAB, Immunoassay Diagnostics (ELISA, chemiluminescence, serology), with a secondary code of HLAHAAAA, Clinical Chemistry & Immunoassay Systems. Its NAICS code is 325413 and its SIC code is 2835.